Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Support Through Remote Observation and Nutrition Guidance Program for Individuals With Pancreatic Cancer Undergoing Surgery (STRONG-PCS)

NCT ID: NCT06001268Sponsor: H. Lee Moffitt Cancer Center and Research InstituteLast updated: 2026-04-01

Summary

The purpose of the study is to assess the feasibility and participant satisfaction with the Support through Remote Observation and Nutrition Guidance program. The program provides enhanced dietician access and nutrition support for participants living with pancreatic cancer who are undergoing surgery.

Arms & interventions

  • BehavioralFitbit Data Collection

    Participants will log food intake while sharing their data with a dietician in real time for 12 weeks

  • BehavioralNutrition Counseling

    Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.

  • BehavioralSurvey

    Participants will take a survey at baseline and weeks 4,8,\& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.

Outcome measures

Primary

  • Recruitment Rate - Feasibility

    The study will be deemed feasible if ≥ 50% of eligible participants are enrolled.

    Time frame: Up to 48 months

  • Retention Rate - Feasibility

    The study will be deemed feasible if ≥ 70% of participants enrolled at baseline will be retained at 8 weeks.

    Time frame: at 8 weeks

  • Data Collection - Feasibility

    The study will be deemed feasible if ≥ 70% of participants log food for greater than 80% of study days.

    Time frame: at 8 weeks

  • Participant Satisfaction - Acceptability

    The study will be deemed acceptable if ≥ 70% of participants rate the overall intervention as satisfactory using a validated 4-item scale (score range 0-20, score \>/= 12).

    Time frame: at 8 weeks

  • Participant Rating on Ease of Use the Mobile Application - Usability

    The study will be deemed usable if ≥ 60% of participants rate the mobile application as easy-to-use for logging dietary intake using a validated 10-item scale (score range from 0-100, score of \>/=60).

    Time frame: at 8 weeks

Secondary

  • Malnutrition-Significant weight loss

    Time frame: 90 days

  • Malnutrition - Low BMI

    Time frame: at Baseline, 30, 60 and 90 days

  • Malnutrition - Low Skeletal Muscle Mass

    Time frame: At baseline, 30, 60 and 90 days

  • Quality of Life

    Time frame: at Baseline, 4, 8 and 12 weeks

  • Hospital Readmissions

    Time frame: 30, 60 and 90 days post-hospital discharge

  • Malnutrition -Nutritional Status

    Time frame: at Baseline, 30, 60 and 90 days

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * ≥18 years old * Diagnosis of pancreatic cancer * Completed open pancreatic surgery (e.g., Whipple, distal/subtotal pancreatectomy, total pancreatectomy) for treatment at Moffitt Cancer Center * Discharged on an oral diet * Able to speak and read English or Spanish * Able to provide informed consent Exclusion Criteria: * Determined to be ineligible for surgery during evaluation (e.g., cancer metastasis)

Study locations (1)

Moffitt Cancer Center

Tampa, Florida, 33612

Recruiting
Kea L Turner, PhD, MPH, MA · Principal Investigator
Pamela J Hodul, MD · Principal Investigator
Amir Alishahi Tabriz, MD, PhD, MPH · Sub Investigator
Brian D Gonzalez, PhD · Sub Investigator
Nate H Parker, MPH, PhD · Sub Investigator
Laurence R Gore, PhD · Sub Investigator

References

  • Turner K, Milano J, Santiago C, Coutinho J, Sprow O, Hume E, Nardella N, Alishahi Tabriz A, Islam JY, Hodul PJ. A patient-mediated strategy to improve nutrition care after transition from hospital to home for pancreatic cancer surgery: a pilot randomised controlled trial study protocol. BMJ Open. 2026 Jan 28;16(1):e113207. doi: 10.1136/bmjopen-2025-113207.(PubMed)